Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy

[1]  C. Wood,et al.  Re: Efficacy of Everolimus in Advanced Renal Cell Carcinoma: A Double-Blind, Randomized, Placebo-Controlled Phase III Trial , 2009 .

[2]  R. Motzer,et al.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.

[3]  J. Knox.  Progression-free survival as endpoint in metastatic RCC? , 2008, The Lancet.

[4]  M. Atkins,et al.  Retrospective analysis of interleukin-2 therapy in patients with metastatic renal cell carcinoma who had received prior antiangiogenic therapy , 2008 .

[5]  R. Roydasgupta,et al.  Array-based comparative genomic hybridization (CGH) identifies chromosomal imbalances between Interleukin-2 complete and non-responders , 2008 .

[6]  Bohuslav Melichar,et al.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.

[7]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[8]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[9]  R. Parker,et al.  Histologic Predictors of Renal Cell Carcinoma Response to Interleukin-2-Based Therapy , 2005, Journal of immunotherapy.

[10]  S. Horvath,et al.  Gene expression and tissue microarray analysis of interleukin-2 complete responders in patients with metastatic renal cell carcinoma , 2005 .

[11]  S. Signoretti,et al.  Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer , 2005, Clinical Cancer Research.

[12]  J. Schalken,et al.  Strict regulation of CAIXG250/MN by HIF-1α in clear cell renal cell carcinoma , 2004, Oncogene.

[13]  S. Steinberg,et al.  Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Steve Horvath,et al.  Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  R. Motzer,et al.  Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Figlin,et al.  Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Gordon,et al.  Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma , 2008 .

[18]  M. Gordon.  Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma , 2006 .

[19]  R. Motzer,et al.  Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.